Table 1.
Demographics and clinical characteristics
| HCs | MDD | P value | |
|---|---|---|---|
| Baseline | |||
| N (F/M) | 34 (22/12) | 35 (23/12) | 0.929a |
| Age (years) | 42.03 ± 13.66 | 43.37 ± 13.87 | 0.687b |
| Education level (years) | 11.71 ± 4.95 | 9.66 ± 5.25 | 0.103b |
| Handedness (R/L) | 34/0 | 35/0 | >0.999a |
| Age of onset | ‐ | 39.90 ± 13.51 | ‐ |
| Disease duration (years) | ‐ | 3.52 ± 3.78 | ‐ |
| Duration of current episode (years) | ‐ | 1.61 ± 1.91 | ‐ |
| Number of episodes | ‐ | 1.51 ± 0.98 | ‐ |
| HAMD | ‐ | 22.71 ± 3.91 | ‐ |
| Follow‐up (2 weeks) | |||
| N (F/M) | 31 (21/10) | 28 (17/11) | 0.573a |
| Age (years) | 41.26 ± 13.54 | 43.14 ± 13.56 | 0.596b |
| Education level (years) | 11.90 ± 4.93 | 9.61 ± 5.30 | 0.090b |
| Handedness (R/L) | 31/0 | 28/0 | >0.999a |
| HAMD | ‐ | 13.07 ± 5.61 | ‐ |
| Medication (N, average dosage) | |||
| Escitalopram | ‐ | 18 (10.6 mg/d) | ‐ |
| Agomelatine | ‐ | 7 (25 mg/d) | ‐ |
| Venlafaxine | ‐ | 2 (150 mg/d) | ‐ |
| Mirtazapine | ‐ | 1 (45 mg/d) | ‐ |
| Follow‐up (12 weeks) | |||
| N (F/M) | 30 (20/10) | 18 (12/6) | >0.999a |
| Age (years) | 42.43 ± 13.94 | 42.67 ± 13.91 | 0.955b |
| Education level (years) | 11.87 ± 4.70 | 10.94 ± 4.96 | 0.522b |
| Handedness (R/L) | 30/0 | 18/0 | >0.999a |
| HAMD | ‐ | 9.06 ± 6.61 | ‐ |
| Medication (n, average dosage) | |||
| Escitalopram | ‐ | 14 (12.9 mg/d) | ‐ |
| Agomelatine | ‐ | 3 (33.3 mg/d) | ‐ |
| Venlafaxine | ‐ | 1 (75 mg/d) | ‐ |
Note. Abbreviations: HAMD = Hamilton Rating Scale for depression; HCs = healthy controls; F = female; M = male; R = right; L = left; MDD = major depressive disorder.
Data are presented as mean ± SD for continuous variables.
a
The p values were obtained by Chi‐square tests.
b
The p values were obtained by two‐sample t tests.